Aromatase inhibitors for breast cancer prevention

Saranya Chumsri, Stephen Yu, Amanda Schech, Gauri Sabnis, Angela Brodie

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

Original languageEnglish (US)
Title of host publicationTrends in Breast Cancer Prevention
PublisherSpringer International Publishing
Pages103-111
Number of pages9
ISBN (Electronic)9783319271354
ISBN (Print)9783319271330
DOIs
StatePublished - Jan 1 2016

Fingerprint

Aromatase Inhibitors
exemestane
Breast Neoplasms
Venous Thromboembolism
Endometrial Neoplasms
Bone
Cardiovascular Diseases
Placebos
Quality of Life
Bone and Bones
Incidence
Therapeutics
anastrozole

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Chemoprevention

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Chumsri, S., Yu, S., Schech, A., Sabnis, G., & Brodie, A. (2016). Aromatase inhibitors for breast cancer prevention. In Trends in Breast Cancer Prevention (pp. 103-111). Springer International Publishing. https://doi.org/10.1007/978-3-319-27135-4_5

Aromatase inhibitors for breast cancer prevention. / Chumsri, Saranya; Yu, Stephen; Schech, Amanda; Sabnis, Gauri; Brodie, Angela.

Trends in Breast Cancer Prevention. Springer International Publishing, 2016. p. 103-111.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chumsri, S, Yu, S, Schech, A, Sabnis, G & Brodie, A 2016, Aromatase inhibitors for breast cancer prevention. in Trends in Breast Cancer Prevention. Springer International Publishing, pp. 103-111. https://doi.org/10.1007/978-3-319-27135-4_5
Chumsri S, Yu S, Schech A, Sabnis G, Brodie A. Aromatase inhibitors for breast cancer prevention. In Trends in Breast Cancer Prevention. Springer International Publishing. 2016. p. 103-111 https://doi.org/10.1007/978-3-319-27135-4_5
Chumsri, Saranya ; Yu, Stephen ; Schech, Amanda ; Sabnis, Gauri ; Brodie, Angela. / Aromatase inhibitors for breast cancer prevention. Trends in Breast Cancer Prevention. Springer International Publishing, 2016. pp. 103-111
@inbook{b40905efb7524d3dabc7d35b3b78b3e5,
title = "Aromatase inhibitors for breast cancer prevention",
abstract = "Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.",
keywords = "Aromatase inhibitors, Breast cancer, Chemoprevention",
author = "Saranya Chumsri and Stephen Yu and Amanda Schech and Gauri Sabnis and Angela Brodie",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-27135-4_5",
language = "English (US)",
isbn = "9783319271330",
pages = "103--111",
booktitle = "Trends in Breast Cancer Prevention",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Aromatase inhibitors for breast cancer prevention

AU - Chumsri, Saranya

AU - Yu, Stephen

AU - Schech, Amanda

AU - Sabnis, Gauri

AU - Brodie, Angela

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

AB - Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Chemoprevention

UR - http://www.scopus.com/inward/record.url?scp=85008957439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008957439&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27135-4_5

DO - 10.1007/978-3-319-27135-4_5

M3 - Chapter

SN - 9783319271330

SP - 103

EP - 111

BT - Trends in Breast Cancer Prevention

PB - Springer International Publishing

ER -